Pharmaceutical compositions of hydrophobic camptothecin derivatives
First Claim
1. A method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression, comprising:
- administering to a subject in need thereof an effective amount of a pharmaceutical composition that comprises;
at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof; and
at least one polyethylene glycol (PEG) conjugated phospholipid;
wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45;
1 to about 1.05;
1.
1 Assignment
0 Petitions
Accused Products
Abstract
Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.
21 Citations
18 Claims
-
1. A method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression, comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition that comprises; at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof; and at least one polyethylene glycol (PEG) conjugated phospholipid; wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45;
1 to about 1.05;
1.
-
2. The method of claim 1, wherein said hydrophobic topoisomerase I inhibitor is selected from the group consisting of:
- an acridine compound, an actinomycin, an anthracycline compound, an anthraquinone compound, a berberine alkaloid, a benzofluoranthene compound, a benzophenanthridine alkaloid, a camptothecin derivative, a DNA minor groove binder, an indolocarbazole compound, a naphthoquinone compound, a flavonoid, a quinoline compound, a terbenzimidazole compound, and a tricyclic carboxamide derivative.
-
3. The method of claim 1, wherein said hydrophobic topoisomerase I inhibitor is selected from the group consisting of:
- aclacinomycin A, 5-acridin-9-ylmethylidene-3-amino-2-thioxothiazolidin-4-one, 5-acridin-9-ylmethylidene-2-thioxoimidazolidin-4-one, 3-acridin-9-ylmethylthiazolidine-2,4-dione, silatecan, 9-aminocamptothecin, gimatecan, karenitecin, diflomotecan, rubitecan, 7-ethylcamptothecin, 10-aminocamptothecin, 10,11-methylenedioxycamptothecin, 9-amino-10,11-methylenedioxycamptothecin, 9-chloro-10,11-methylenedioxycamptothecin, TLC388, TLC1988, actinomycin D, NU/ICRF 505, epiberberine, coralyne, beta-lapachone, nitidine, fagaronine, corilagin, rebeccamycin, KT6006, KT6528, ED-110, NB-506, alkannin, shikonin, EMD 21388, EMD 50689, acacetin, kaempferol, saintopin, 5-phenyl-terbenzimidazole (5PTB), topostatin, topostin B567, and intoplicine.
-
4. The method of claim 1, wherein said hydrophobic topoisomerase I inhibitor is a compound having a water solubility less than camptothecin.
-
5. The method of claim 4, wherein said hydrophobic topoisomerase I inhibitor is a compound having a water solubility less than 0.511 mg/mL.
-
6. The method of claim 1, further comprising at least one pH adjusting agent.
-
7. The method of claim 1, further comprising at least one pharmaceutically acceptable excipient or carrier.
-
8. The method of claim 1, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.60:
- 1 to about 1.00;
1.
- 1 to about 1.00;
-
9. The method of claim 1, wherein said pharmaceutical composition has a pH less than about 4.
-
10. The method of claim 1, wherein the PEG conjugated phospholipid comprises a PEG moiety having a molecular weight from about 1,000 to about 20,000 daltons conjugated to a phospholipid moiety.
-
11. The method of claim 1, wherein the PEG conjugated phospholipid is a PEG-DSPE conjugate.
-
12. The method of claim 1, wherein the hydrophobic topoisomerase I inhibitor or the pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor and PEG conjugated phospholipid form micelles with a size less than about 40 nm.
-
13. The method of claim 1, wherein the hydrophobic topoisomerase I inhibitor comprises one or more electron-affinic moieties being directly or indirectly attached to one of the carbons at the C5, C7, C9, C10, C11, C12 or C20 position of camptothecin.
-
14. The method of claim 1, wherein the hydrophobic topoisomerase I inhibitor is a camptothecin derivative having a planar pentacyclic ring structure.
-
15. The method of claim 13, wherein said camptothecin derivative is selected from the group consisting of:
- silatecan, 9-aminocamptothecin, gimatecan, karenitecin, diflomotecan, rubitecan, 7-ethylcamptothecin, 10-aminocamptothecin, 10,11-methylenedioxycamptothecin, 9-amino-10,11-methylenedioxycamptothecin, 9-chloro-10,11-methylenedioxycamptothecin, TLC388, and TLC1988.
-
16. The method of claim 6, wherein the pH adjusting agent is tartaric acid or citric acid.
-
17. The method of claim 1, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.70:
- 1 to about 0.90;
1.
- 1 to about 0.90;
-
18. The method of claim 11, wherein the PEG-DSPE conjugate is a methoxyl PEG-DSPE conjugate.
Specification